Bruker Corporation
—- Market cap
- $8.16B
- Debt
- —
- Cash
- −$298.80M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: BRKR stock price at discount vs ABT $53.56 current versus $91.61 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ABT's multiple
Implied fair value · at BRKR's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BRUKER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ABBOTT LABORATORIES · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
THERMO FISHER SCIENTIFIC INC.
BRKR vs TMO
DANAHER CORP /DE/
BRKR vs DHR
AGILENT TECHNOLOGIES, INC.
BRKR vs A
WATERS CORP /DE/
BRKR vs WAT
BIO-RAD LABORATORIES, INC.
BRKR vs BIO
BIO-TECHNE Corp
BRKR vs TECH
Johnson & Johnson
BRKR vs JNJ
Medtronic plc
BRKR vs MDT
BECTON DICKINSON & CO
BRKR vs BDX
BOSTON SCIENTIFIC CORP
BRKR vs BSX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BRKR can materially expand margins and reduce leverage toward ABT-like levels, then reconsider the discount because the current valuation assumes a much stronger earnings profile than the data shows; otherwise, the stock looks better avoided or underweighted versus ABT.
BRKR’s implied price of $96.04 sits 87.3% above the current price of $51.27, but the underlying operating profile does not support that premium versus ABT. On relative multiples, BRKR trades at 2.3x P/S and 28.8x EV/EBITDA versus ABT at 4.2x P/S and 15.3x EV/EBITDA, indicating BRKR is cheaper on sales but more expensive on earnings power.
Supporting Metrics